Skip to content

A dose-effect study of HFNC contributing to safety for over-weight and obesity patients during gastrointestinal endoscopy with sedation

A dose-effect study of HFNC contributing to safety for over-weight and obesity patients during gastrointestinal endoscopy with sedation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044636
Enrollment
Unknown
Registered
2021-03-25
Start date
2021-03-25
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroenteroscopy with deep sedation

Interventions

Group HFNC 6L/min:Set the flow rate as 6L/min,FiO2 50% and temperature 34 degrees C
Group HFNC 20L/min:Set the flow rate as 20L/min,FiO2 50% and temperature 34 degrees C
Group HFNC 40L/min:Set the flow rate as 40L/min,FiO2 50% and temperature 34 degrees C
Group HFNC 60L/min:Set the flow rate as 60L/min,FiO2 50% and temperature 34 degrees C

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. BMI (body mass index) >= 24. 2. Aged >= 18 years old. 3. Regardless of gender and ethnicity. 4. Patients undergo non-emergency gastrointestinal endoscopy with deep sedation, and the procedure lasts more than 15mins. 5. ASA scores 1-3. 6. Patients sign the informed consent form willingly.

Exclusion criteria

Exclusion criteria: 1. Patient with mental or neurological diseases or suspected dementia or memory impairment. 2. Patient with severe auditory, visual, and language system impairment. 3. Patient with confirmed/suspected abuse or long-term use of narcotic sedative analgesics. 4. Patient whose nasal cavity is obstructed and unable to ventilate through the nose. 5. Patient who have contraindications or allergies to propofol and sufentanil. 6. Patient who have symptoms such as cough and sputum in the acute stage of upper respiratory tract infection. 7. Full stomach, fasting for less than 8 hours, drinking less than 2 hours and the last laxative was taken less than 3 hours from the time of diagnosis and treatment. 8. Patient who did not undergo surgery for achalasia and suspected that there is a high risk of reflux and aspiration for upper gastrointestinal obstruction. 9. Doctor or researcher who perform endoscopy believes that there are other conditions that are not suitable for participating in this study.

Design outcomes

Primary

MeasureTime frame
whether hypoxemia occurs;number of occurrences of hypoxemia;safe time limit;the minimun SpO2;Respiratory management interventions such as jaw support, oxygen inhalation, pharyngeal airway placement, mask ventilation assisted breathing, tracheal intubation;

Secondary

MeasureTime frame
the Highest end-tidal carbon dioxide;hemodynamics;First bolus of propofol;total propofol dosage;Duration of diagnosis and treatment;Duration of anesthesia;Diagnosis of gastrointestinal endoscopy;The relative relationship between epiglottis and glottis;Airway assessment such as snoring history, OSAHS screening (STOP-Bang score), head and neck mobility, neck circumference, mandibular development and extension, mouth opening, Mallampati classification, thyromental Distance;

Countries

China

Contacts

Public ContactSongshan Li

Shenzhen Second People's Hospital

43414004@qq.com+86 13510710648

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026